Načítá se...
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. A Phase 2b/3 clinical trial recently published in The Lancet Infectious Diseases found that o...
Uloženo v:
| Vydáno v: | Antiviral Res |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Author. Published by Elsevier B.V.
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7113776/ https://ncbi.nlm.nih.gov/pubmed/25108173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2014.07.014 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|